Free Newsletter
FEATURES >> The most interesting logos in Pharma
Sanofi's Lovenox patents 'unenforceable'
Will the way soon be clear for a generic form of Lovenox? Sanofi-Aventis just lost a bid to save its patents on the anticlotting med, as a U.S. appeals court upheld a lower-court ruling that called the patents unenforceable. That court found that Sanofi failed to disclose certain info on its patent applications--"inequitable conduct" that negated their protection.
The ruling is a win for Teva Pharmaceutical Industries and Amphastar Pharmaceuticals, which originally challenged the patents. They both applied for FDA approval for copycat forms of the med back in 2003. Lovenox's key patent was set to expire in 2012; Sanofi says it's "considering its legal options."
- read the Wall Street Journal news
Related Articles:
Sanofi loses Lovenox patent protection
Lovenox reduces cardio risks but can cause bleeding
Momenta sees delay in generic Lovenox development
Comments
Is there updated info on the status of generic Lovenox?
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
SHARE
WITH: